Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01552070 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS)

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the change of extravascular lung water (EVLW), cytokine and oxygenation parameters in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) after alveolar recruitment maneuver.

NCT ID: NCT01551225 Completed - Clinical trials for Irritable Bowel Syndrome

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Start date: January 2012
Phase: Phase 4
Study type: Interventional

This study will be executed according to a randomized double-blind placebo-controlled trial with two parallel groups, treated over the period of 6 months with escitalopram or placebo. Hypotheses: Escitalopram is more effective than placebo in the control of gastrointestinal symptoms, in irritable bowel syndrome (IBS) patients with panic disorder. Escitalopram is more effective than placebo in the control of psychiatric symptoms, in IBS patients with panic disorder.

NCT ID: NCT01549847 Withdrawn - Clinical trials for Postpoliomyelitis Syndrome

A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome

Start date: n/a
Phase: Phase 3
Study type: Interventional

This protocol aims to assess of L-carnitine and piracetam to relieve weakness, muscle fatigue and muscle pain in patients with Postpoliomyelitis Syndrome.

NCT ID: NCT01548495 Unknown status - Clinical trials for Myelodysplatic Syndrome

Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients

MDS
Start date: May 2012
Phase: N/A
Study type: Observational

The purpose of this study is to verify the presents of autoantibodies in serums of MDS serum patients who had an inadequate response or did not respond to Recombinant human erythropoietin (rHuEPO) treatment.

NCT ID: NCT01547117 Completed - Clinical trials for Postural Orthostatic Tachycardia Syndrome

Dietary Salt in Postural Tachycardia Syndrome

Start date: March 2012
Phase: N/A
Study type: Interventional

Patients with POTS may not adequately expand their plasma volume in response to a high-sodium (Na+) diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine, may be impaired in POTS and may respond inappropriately to changes in dietary sodium.The purpose of this study is to determine (1) whether a high dietary sodium level appropriately expands plasma volume in POTS; (2) whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in POTS; and (3) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.

NCT ID: NCT01547013 Active, not recruiting - Clinical trials for Anterior Tibial Compartment Syndrome

The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients

NIRS
Start date: February 2012
Phase:
Study type: Observational

This is a study intended to evaluate a new device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations. The name of this technology is NIRS (near-infrared spectroscopy). This is a prospective observational cohort study intended to gather data using NIRS among injured and noninjured extremities over time. Additionally, this data will help in establishing diagnostic perfusion value thresholds to be used in a subsequent interventional study confirming the efficacy of NIRS-based ACS monitoring.

NCT ID: NCT01546337 Terminated - Anemia Clinical Trials

Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome

EPO
Start date: May 2008
Phase: N/A
Study type: Observational

Anemia is common among cancer patients and the treatment of choice is now Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment. The purpose of this study is to evaluate the predictive value of endogenous erythropoietin rate on the response to erythropoietin beta. First, by confirming the predictive value of endogenous erythropoietin observed / predicted ratio on this response. Then if it is confirmed by establishing the optimal value of this ratio.

NCT ID: NCT01545830 Completed - Metabolic Syndrome Clinical Trials

Metabolic Syndrome and Insulin Resistance at Allina

MISURA
Start date: March 2012
Phase: Phase 2
Study type: Interventional

Vitamin D deficiency is widespread and appears to represent one easily and inexpensively modifiable risk factor for diabetes and cardiovascular disease. More than 40 years of data link hypovitaminosis D to metabolic syndrome, insulin resistance, hyperglycemia, type 2 diabetes and increased cardiovascular risk. Screening for vitamin D deficiency followed by supplementation in appropriate individuals could be among the simplest and most cost-effective measures for reducing metabolic syndrome and insulin resistance in the general population. This study will test the hypothesis that increasing vitamin D status in vitamin D deficient individuals with metabolic syndrome will: 1. reduce multiple serum cardiometabolic risk factors for both diabetes and cardiovascular disease, 2. stabilize or reverse the stage of pre-diabetes, 3. improve quality of life, and, 4. improve the ability to make health-related behavioral changes.

NCT ID: NCT01545323 Recruiting - Netherton Syndrome Clinical Trials

Gene Therapy for Netherton Syndrome

Start date: April 2014
Phase: Phase 1
Study type: Interventional

Netherton Syndrome is a serious skin disorder caused by damage in a gene called SPINK5. This gene controls the formation of a protein called LEKTI, which important for skin barrier function. LEKTI inhibits certain enzymes (serine proteinases) in the outermost layer of the skin (epidermis). The function of the serine proteinases is to break down the intracellular cement that holds together the horny cells in the epidermis, in order for the skin to be able to shed cells (known as cell desquamation). LEKTI deficiency leads to an uninhibited desquamation of horny cells, and as a result the skin becomes red and scaly. The barrier function of the skin is also affected. The permeability of the skin increases, and its capacity to bind water decreases, which causes dryness. The thinness of the barrier also results in over absorption of chemicals, for example topical medical treatments. Historically one in ten infants dies before their first birthday. Currently there are no proven treatments to cure this condition. The investigators have been developing a gene therapy approach to treat this disorder. The investigators have used a disabled virus (vector) to carry a functional copy of the SPINK5 gene into skin stem cells. Proof-of-principle experiments have shown the investigators can restore almost normal shape and size of the upper layer of the skin in skin grafts grown in the lab. Even if only a small number of cells are genetically modified to carry the corrected SPINK5 gene, there seems to be a correction over a wide area of the graft. In this trial the investigators propose grafting of autologous epidermal sheets generated from genetically modified skin stem cells for the treatment of patients with Netherton Syndrome. The investigators anticipate production and release of LEKTI protein from even a small patch of skin will be beneficial.

NCT ID: NCT01545037 Completed - Clinical trials for Irritable Bowel Syndrome

Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.